← FDA DRUG APPROVALS

FDA NDA · NDA019151

RYTHMOL

Sponsor: GLAXOSMITHKLINE LLC

APPLICATION
NDA019151
TYPE
NDA
ORIGINAL APPROVAL
1989-11-27
LATEST ACTION
2018-11-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

RYTHMOL · ReferenceDiscontinued
PROPAFENONE HYDROCHLORIDE 225MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
RYTHMOL · ReferenceDiscontinued
PROPAFENONE HYDROCHLORIDE 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
RYTHMOL · ReferenceDiscontinued
PROPAFENONE HYDROCHLORIDE 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2018-11-02Labeling · Supplement 15 · standardLabelAP
2014-07-11Manufacturing (CMC) · Supplement 13 · standardAP
2013-03-20Labeling · Supplement 12 · unknownLetterAP
2002-12-05Labeling · Supplement 9 · standardLetterAP
2002-12-05Labeling · Supplement 5 · standardLetterAP
2002-01-11Manufacturing (CMC) · Supplement 10 · standardAP
2000-12-21Manufacturing (CMC) · Supplement 8 · standardAP
2000-07-14Manufacturing (CMC) · Supplement 7 · standardAP
1999-09-24Manufacturing (CMC) · Supplement 6 · standardAP
1997-12-23Efficacy · Supplement 2 · unknownReviewAP
1997-03-19Labeling · Supplement 4 · standardAP
1993-11-23Manufacturing (CMC) · Supplement 3 · standardAP
1992-11-20Manufacturing (CMC) · Supplement 1 · standardAP
1989-11-27Type 1 - New Molecular Entity · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →